Canadian drug patent bill
Amendments to Canada's Patent Act, introduced in the House of Commons Nov. 6, would prevent market entrance of generic drugs until seven years after a patent is issued for the brandname drug. The language of the bill is almost identical to draft legislation announced in June ("The Pink Sheet" July 7, T&G-3). The amendments would allow for marketing exclusivity to be reduced or eliminated four years after the exclusivity provisions go into effect -- if an independent drug price review board determines that a drug is being sold at an excessive price.
You may also be interested in...
COVID-19 has disrupted the operational schedules of health care and technology providers alike to unparalleled levels in 2020. But scratch the surface, and outcomes-oriented, value-based health care targets remains a priority – albeit competing a little harder for attention at present.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Kim Trautman, who authored the US FDA’s Quality System Regulation in the 1990s, tells Medtech Insight that the agency probably won’t release a draft of its updated, harmonized QSR until next year thanks in part to a recent move by HHS secretary Alex Azar to personally sign off on every rule.